CinCor Pharma is a clinical-stage biopharmaceutical firm based in Boston, Massachusetts. The company invents treatments for cardio-renal diseases, with its primary focus on CIN-107, now in Phase II clinical trials, to treat hypertension, primary aldosteronism, cardio-renal ailments as well as Phase I clinical trial for the treatment of chronic kidney diseases. CinCor Pharma has a partnership with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc, and was founded in 2018.